, Tracking Stock Market Picks
Enter Symbol:
Cyberonics, Inc. (CYBX) [hlAlert]

up 375.51 %

Cyberonics, Inc. (CYBX) rated Buy with price target $21 by Lazard Capital Mkts

Posted on: Wednesday,  Mar 18, 2009  9:25 AM ET by Lazard Capital Mkts

Lazard Capital Mkts rated Buy Cyberonics, Inc. (NASDAQ: CYBX) on 03/18/2009, when the stock price was $14.05. Since
then, Cyberonics, Inc. has gained 375.52% as of 10/16/2016's recent price of $66.81.
If you would have followed this Lazard Capital Mkts's recommendation on CYBX, you would have gained 375.51% of your investment in 2769 days.

Cyberonics, Inc. was founded to design, develop and market medical devices for the treatment of epilepsy and other debilitating neurological disorders using a therapy, vagus nerve stimulation. The company's initial target market is epilepsy, the world's second most prevalent neurological disorder, which is characterized by seizures. Vagus nerve stimulation with the Cyberonics NCP System was approved for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents with medically refractory partial onset seizures. (PRESS RELEASE)

Lazard Capital Markets’ research team is broadly recognized for its insight, thoroughness, and objectivity. Lazard Capital Markets’ goal is to help our clients make the best-informed decisions by providing timely, thoughtful analysis as well as access to company management teams and industry thought leaders. Lazard Capital Markets’ industry-focused analysts strive to identify emerging sector trends as well as bottom-up fundamental issues affecting their stocks under coverage. We add value by conducting extensive primary survey work, hosting proprietary events, cultivating industry contacts, and participating in relevant industry conferences.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/18/2009 9:25 AM Buy
14.05 21.00
as of 12/31/2009
1 Week up  57.16 %
1 Month up  82.83 %
3 Months up  106.46 %
1 YTD up  134.23 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy